Latest news
Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Increased to Strong-Buy at Zacks Research - MarketBeatMarketBeat · Sat, 08 Aug 2026 11:44:17 GMTSupernus Pharmaceuticals (NASDAQ:SUPN) Cut to "Hold" at Wall Street Zen - MarketBeatMarketBeat · Sat, 08 Aug 2026 05:18:55 GMTSupernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN - Business WireBusiness Wire · Fri, 07 Aug 2026 15:21:00 GMTMillennium group (SUPN) reports Supernus stake falls below 5% ownership - Stock TitanStock Titan · Thu, 06 Aug 2026 22:49:12 GMTRx Rundown: Supernus Pharmaceuticals, TCGX, Sandoz and more - Medical Marketing and MediaMedical Marketing and Media · Thu, 06 Aug 2026 13:33:55 GMTSupernus Pharmaceuticals (SUPN) Jumps On Merger Terms, Is The Stock Still Cheap? - simplywall.stsimplywall.st · Thu, 06 Aug 2026 06:36:02 GMTsupernus pharmaceuticals, inc. Positive Earnings Pre-Announcements - RTTNewsRTTNews · Wed, 05 Aug 2026 22:32:34 GMTSupernus And Indivior To Merge And Create $2.2 Billion CNS Biopharmaceutical Company - Pulse 2.0Pulse 2.0 · Wed, 05 Aug 2026 16:41:40 GMT